Comparison
Omega-3 (DHA/EPA) vs Idebenone
Omega-3 (DHA/EPA)
Essential fatty acids critical for brain structure and function. DHA comprises ~40% of brain polyunsaturated fatty acids.
Idebenone
Synthetic analog of CoQ10. Crosses the BBB more efficiently than CoQ10 itself. Approved in Europe and Japan for some neurological conditions.
| Field | Omega-3 (DHA/EPA) | Idebenone |
|---|---|---|
| Category | neuroprotective | neuroprotective |
| Dose range | 1000–3000mg | 90–270mg |
| Half-life | 24h | — |
| Onset | — | — |
| Evidence | EVIDENCEA | EVIDENCEB |
| Safety | ●●●●● | ●●●●○ |
| Legal (US) | USOTC | USOTC |
| PubMed refs | 5200 | 1100 |
The comparison in plain English
Auto-generated from dataOmega-3 (DHA/EPA) and Idebenone are both in the neuroprotective category respectively. Omega-3 (DHA/EPA) Essential fatty acids critical for brain structure and function. Idebenone Synthetic analog of CoQ10.
Bottom line
Omega-3 (DHA/EPA) (evidence A, safety 5/5) has a weaker evidence base than Idebenone (evidence B, safety 4/5). Omega-3 (DHA/EPA) has the slightly cleaner safety profile. For users new to either, the higher-evidence option is the safer first try.
Choose Omega-3 (DHA/EPA) if
Omega-3 (DHA/EPA) is the better fit when your goal aligns with its mechanism (DHA (docosahexaenoic acid) is a structural component of neuronal cell membranes, maintaining fluidity and supporting receptor function) and the dose range (1000–3000mg) suits your protocol. Half-life is 24h.
Choose Idebenone if
Idebenone is the better fit when your goal aligns with its mechanism (Structural analog of CoQ10 with shorter side chain, producing better water solubility and BBB crossing) and the dose range (90–270mg) suits your protocol. Half-life is —h.